Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

The updated 2025-2026 COVID-19 vaccines are now widely available, but with some new limitations. Who can get the shot this ...

Novavax Inc on Monday pushed back the start of a U.S.-based, late-stage trial for its experimental COVID-19 vaccine for the second time and now expects it to begin in the coming weeks instead of ...

Novavax transfers EU rights for Nuvaxovid to Sanofi, earning milestone payments and future royalties. Read more here.

Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding ...

Novavax Inc on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing ...

GoodRx reports that CDC now recommends COVID-19 vaccinations be decided with healthcare professionals, stressing personalized ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles.

On Oct. 3, the Food and Drug Administration (FDA) authorized the updated COVID-19 vaccine by Novavax for people ages 12 and older. The Centers for Disease Control and Prevention and its advisory panel ...

Novavax (NVX-CoV2373) is a brand-name vaccine that’s prescribed to help prevent COVID-19. As with other drugs, Novavax can cause side effects, such as pain or swelling at the injection site. Novavax ...

Shares of COVID-19 vaccine maker Novavax cratered Tuesday as the U.S. biotech company slashed its sales forecast due to a slump in demand for its shots. The company's stock dived 31% after it cut its ...